During a monthslong legal dispute between Merck and John Hopkins University over Keytruda patents, the drugmaker raised the issue to the U.S. Patent and Trademark Office, JD Supra reported March 13.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
